Given the interplay between EAT, metabolic dysregulation, and inflammatory biomarkers, this study aims to investigate the association between EATv, and novel biomarkers related with inflammation and HF (GDF15, Galectin-3, and sST2) in newly diagnosed T2D patients, as well as to determine the effect of glycemic optimization on this association. Here, LGALS3 is linked to type 2 diabetes mellitus.